KRAS and lung adenocarcinoma: This finding has stimulated the synthesis of compounds capable of occupying this space in a stable manner, provided that they could form a covalent bond with the mutant cysteine residue present at position 12 in the KRASG12C oncoprotein, the most frequent oncogenic KRAS variant in human lung adenocarcinomas (LUADs) (3).